157 related articles for article (PubMed ID: 25186485)
21. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Muthu Raja KR; Kovarova L; Hajek R
Leuk Lymphoma; 2012 Jul; 53(7):1406-8. PubMed ID: 22200079
[No Abstract] [Full Text] [Related]
22. Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Fukushima T; Nakamura T; Iwao H; Umehara H
Am J Hematol; 2011 Oct; 86(10):893. PubMed ID: 21812018
[No Abstract] [Full Text] [Related]
23. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
27. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
[TBL] [Abstract][Full Text] [Related]
28. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR
Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694
[TBL] [Abstract][Full Text] [Related]
29. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
[TBL] [Abstract][Full Text] [Related]
30. [Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma].
Liu HB; Chen LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):498-501. PubMed ID: 27151018
[TBL] [Abstract][Full Text] [Related]
31. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
Asou N; Izuno Y; Okubo T; Ide K; Ueno H; Kawakita M; Mitsuya H; Hata H
Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide in multiple myeloma: current role and future directions.
Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in multiple myeloma.
Kim Y; Schmidt-Wolf IG
Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
[TBL] [Abstract][Full Text] [Related]
35. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Mitani Y; Usami E; Kimura M; Nakao T; Okada K; Matsuoka T; Kokuryou T; Yoshimura T; Yamakawa M
Pharmazie; 2016 Jun; 71(6):349-51. PubMed ID: 27455556
[TBL] [Abstract][Full Text] [Related]
37. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
Rosovsky R; Hong F; Tocco D; Connell B; Mitsiades C; Schlossman R; Ghobrial I; Lockridge L; Warren D; Bradwin G; Doyle M; Munshi N; Soiffer RJ; Anderson KC; Weller E; Richardson P
Br J Haematol; 2013 Feb; 160(3):351-8. PubMed ID: 23240658
[TBL] [Abstract][Full Text] [Related]
38. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
39. 5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Ortega M; Mallo M; Solé F; Sánchez-Morata C; López-Andreoni L; Martínez-Morgado N; Gironella M; Valcárcel D; Vallespí T
Leuk Res; 2013 Oct; 37(10):1248-50. PubMed ID: 23891188
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma.
Bettolini L; Bighetti S; Maione V; Ghini I; Segala D; Calzavara-Pinton P
Australas J Dermatol; 2024 Jun; 65(4):e104-e107. PubMed ID: 38326991
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
